BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 20443055)

  • 1. Functional implication of TRAIL -716 C/T promoter polymorphism on its in vitro and in vivo expression and the susceptibility to sporadic breast tumor.
    Pal R; Gochhait S; Chattopadhyay S; Gupta P; Prakash N; Agarwal G; Chaturvedi A; Husain N; Husain SA; Bamezai RN
    Breast Cancer Res Treat; 2011 Apr; 126(2):333-43. PubMed ID: 20443055
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CASP8 polymorphisms, estrogen and progesterone receptor status, and breast cancer risk.
    Han S; Lee KM; Choi JY; Park SK; Lee JY; Lee JE; Noh DY; Ahn SH; Han W; Kim DH; Hong YC; Ha E; Yoo KY; Kang D
    Breast Cancer Res Treat; 2008 Jul; 110(2):387-93. PubMed ID: 17940865
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Promoter polymorphisms in matrix metalloproteinases and their inhibitors: few associations with breast cancer susceptibility and progression.
    Lei H; Hemminki K; Altieri A; Johansson R; Enquist K; Hallmans G; Lenner P; Försti A
    Breast Cancer Res Treat; 2007 May; 103(1):61-9. PubMed ID: 17033924
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel T-77C polymorphism in DNA repair gene XRCC1 contributes to diminished promoter activity and increased risk of non-small cell lung cancer.
    Hao B; Miao X; Li Y; Zhang X; Sun T; Liang G; Zhao Y; Zhou Y; Wang H; Chen X; Zhang L; Tan W; Wei Q; Lin D; He F
    Oncogene; 2006 Jun; 25(25):3613-20. PubMed ID: 16652158
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Death receptor 4 (DR4) efficiently kills breast cancer cells irrespective of their sensitivity to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL).
    Kazhdan I; Marciniak RA
    Cancer Gene Ther; 2004 Oct; 11(10):691-8. PubMed ID: 15354201
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association between polymorphisms of the BRCA2 gene and clinical parameters in breast cancer.
    Krupa R; Sliwinski T; Morawiec Z; Pawlowska E; Zadrozny M; Blasiak J
    Exp Oncol; 2009 Dec; 31(4):250-1. PubMed ID: 20010525
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic polymorphisms in the MMP-2 and MMP-9 genes and breast cancer phenotype.
    Grieu F; Li WQ; Iacopetta B
    Breast Cancer Res Treat; 2004 Dec; 88(3):197-204. PubMed ID: 15609121
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic variants in the tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) do not contribute but Death Receptor (DR4) genes may contribute to susceptibility to head and neck cancer in Pakistani population.
    Sarwar R; Mansoor Q; Farooqi AA; Shahzad S; Fayyaz S; Ismail M
    Cell Mol Biol (Noisy-le-grand); 2015 Dec; 61(8):53-6. PubMed ID: 26718429
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MDR1 C3435T polymorphism in patients with breast cancer.
    Turgut S; Yaren A; Kursunluoglu R; Turgut G
    Arch Med Res; 2007 Jul; 38(5):539-44. PubMed ID: 17560460
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A study on the association of cytochrome-P450 1A1 polymorphism and breast cancer risk in north Indian women.
    Singh V; Rastogi N; Sinha A; Kumar A; Mathur N; Singh MP
    Breast Cancer Res Treat; 2007 Jan; 101(1):73-81. PubMed ID: 16807674
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Methyl-CpG binding domain 1 gene polymorphisms and risk of primary lung cancer.
    Jang JS; Lee SJ; Choi JE; Cha SI; Lee EB; Park TI; Kim CH; Lee WK; Kam S; Choi JY; Kang YM; Park RW; Kim IS; Cho YL; Jung TH; Han SB; Park JY
    Cancer Epidemiol Biomarkers Prev; 2005 Nov; 14(11 Pt 1):2474-80. PubMed ID: 16284366
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A polymorphism in the TC21 promoter associates with an unfavorable tamoxifen treatment outcome in breast cancer.
    Rokavec M; Schroth W; Amaral SM; Fritz P; Antoniadou L; Glavac D; Simon W; Schwab M; Eichelbaum M; Brauch H
    Cancer Res; 2008 Dec; 68(23):9799-808. PubMed ID: 19047159
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A functional -77T>C polymorphism in XRCC1 is associated with risk of breast cancer.
    Liu L; Yuan P; Liu L; Wu C; Zhang X; Guo H; Zhong R; Xu Y; Wu J; Duan S; Rui R; Wu T; Nie S; Miao X; Lin D
    Breast Cancer Res Treat; 2011 Jan; 125(2):479-87. PubMed ID: 20549339
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interleukin-6 -174G-->C polymorphism is associated with improved outcome in high-risk breast cancer.
    DeMichele A; Martin AM; Mick R; Gor P; Wray L; Klein-Cabral M; Athanasiadis G; Colligan T; Stadtmauer E; Weber B
    Cancer Res; 2003 Nov; 63(22):8051-6. PubMed ID: 14633738
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A genetic variant in p63 (rs17506395) is associated with breast cancer susceptibility and prognosis.
    Zhang N; Huo Q; Wang X; Chen X; Long L; Guan X; Jiang L; Ma T; Hu W; Yang Q
    Gene; 2014 Feb; 535(2):170-6. PubMed ID: 24316488
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel polymorphism in the promoter region of ERBB4 is associated with breast and colorectal cancer risk.
    Rokavec M; Justenhoven C; Schroth W; Istrate MA; Haas S; Fischer HP; Vollmert C; Illig T; Hamann U; Ko YD; Glavac D; Brauch H
    Clin Cancer Res; 2007 Dec; 13(24):7506-14. PubMed ID: 18094435
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of common PALB2 polymorphisms with breast cancer risk: a case-control study.
    Chen P; Liang J; Wang Z; Zhou X; Chen L; Li M; Xie D; Hu Z; Shen H; Wang H
    Clin Cancer Res; 2008 Sep; 14(18):5931-7. PubMed ID: 18794107
    [TBL] [Abstract][Full Text] [Related]  

  • 18. P27 V109G Polymorphism is associated with lymph node metastases but not with increased risk of breast cancer.
    Naidu R; Har YC; Taib NA
    J Exp Clin Cancer Res; 2007 Mar; 26(1):133-40. PubMed ID: 17550142
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification and functional characterization of a highly polymorphic region in the human TRAIL promoter in multiple sclerosis.
    Weber A; Wandinger KP; Mueller W; Aktas O; Wengert O; Grundström E; Ehrlich S; Windemuth C; Kuhlmann T; Wienker T; Brück W; Zipp F
    J Neuroimmunol; 2004 Apr; 149(1-2):195-201. PubMed ID: 15020080
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Functional polymorphisms in FAS and FASL contribute to increased apoptosis of tumor infiltration lymphocytes and risk of breast cancer.
    Zhang B; Sun T; Xue L; Han X; Zhang B; Lu N; Shi Y; Tan W; Zhou Y; Zhao D; Zhang X; Guo Y; Lin D
    Carcinogenesis; 2007 May; 28(5):1067-73. PubMed ID: 17183065
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.